Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances

Simply Wall St.03-26

Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622858681?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-26 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622858681","market":"hk","top_or_hot":-1,"title":"Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances","media":"Simply Wall St.","content":"<div>\n<p>Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akeso Advances Next Generation Oncology Pipeline With New Trial Clearances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkeso Advances Next Generation Oncology Pipeline With New Trial Clearances\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 15:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720050803.USD","symbol_name":"安联全方位中国股票基金","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr","article_id":"2622858681","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-advances-next-generation-oncology-pipeline-with-new-tr","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622858681","pubTimestamp":1774508839,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology.\nThe company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors.\nThese approvals move multiple assets in Akeso's pipeline into clinical and mid stage development.\n\nFor investors tracking Akeso (SEHK:9926), these clearances come with the stock...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","09926":"康方生物","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC"},"translate_title":"康方生物通过新的试验许可推进下一代肿瘤产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":0.9},"content_text":"Akeso received regulatory clearance in China to start Phase II trials for two next generation antibody drug conjugates, AK146D1 and AK138D1, in oncology. The company also secured clearance for AK150, a globally first in class trispecific antibody, to begin clinical trials in patients with advanced solid tumors. These approvals move multiple assets in Akeso's pipeline into clinical and mid stage development.  For investors tracking Akeso (SEHK:9926), these clearances come with the stock trading at HK$121.8 and a 1 year return of 77.9%. Over 3 years the share price return stands at 196.0%, with a 5 year return of 148.1%, indicating that the market has already assigned meaningful value to the company’s oncology pipeline. The advancement of AK146D1, AK138D1 and AK150 into clinical and Phase II studies adds more real world readouts to monitor in the coming years. Investors may want to focus on trial design, safety signals and early efficacy data as they emerge, as these factors will influence how much commercial and clinical weight these programs could carry for Akeso over time. Stay updated on the most important news stories for Akeso by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Akeso. SEHK:9926 Earnings & Revenue Growth as at Mar 2026 We've flagged 0 risks for Akeso. See which could impact your investment. These clearances deepen Akeso's push into next generation oncology combinations, which is an area where global peers such as Seagen, Daiichi Sankyo and AstraZeneca are also active. By pairing AK146D1 and AK138D1 with existing bispecific backbones like cadonilimab and ivonescimab, Akeso is trying to build a proprietary treatment ecosystem around its own assets rather than relying on external partners. If future data support the early signals on efficacy and safety, this kind of portfolio approach could help the company address multiple tumor types and lines of therapy, which is often important for building a durable revenue base. AdvertisementHow This Fits Into The Akeso Narrative  This news lines up with the narrative that Akeso's bispecific antibodies and broader pipeline could support long term earnings, because it expands the use cases for cadonilimab and ivonescimab through combination regimens. The heavy investment in new trials may also weigh on profitability in the near term, which challenges the narrative that margin improvement will come easily while the company is still loss making. The trispecific AK150 and ADC combinations are not fully captured in a storyline that focuses mainly on late stage immuno oncology assets, so their impact on future opportunities may be understated.  Knowing what a company is worth starts with understanding its story.\n                        Check out one of the top narratives in the Simply Wall St Community for Akeso to help decide what it is worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Clinical and regulatory risk remains high for AK146D1, AK138D1 and AK150, and setbacks across several studies could affect confidence in Akeso's broader pipeline. ⚠️ A growing trial footprint increases R&D spending, which may add pressure to a business that already reports operating and EBITDA losses. 🎁 The progression of multiple next generation assets into Phase II and first in human trials broadens Akeso's potential addressable market across several solid tumor types. 🎁 Combinations built on internal drugs such as cadonilimab and ivonescimab can deepen product moats and may support more resilient revenue if key regimens gain clinical traction.  What To Watch Going Forward From here, keep an eye on initial safety and efficacy readouts for the AK146D1 and AK138D1 combinations, especially in tumor types where other ADCs are already available. For AK150, early clinical data on tolerability and signs of immune activation will be important, given it is a first in class trispecific approach. Investors may also want to track how R&D spending trends against any future revenue contribution from existing products, because that balance will influence how sustainable Akeso's current pace of pipeline expansion is. To stay informed about how the latest news impacts the investment narrative for Akeso, head to the\n                        community page for Akeso to keep up with the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622858681","isCrawlerRequest":true}